Sensorion appoints Peter Weber as Chief Medical Officer

Biotechnology company Sensorion announced the appointment of Peter Weber, MD, MBA, as Chief Medical Officer, effective November 2, 2026. An otologist and neurotologist, Dr. Weber has 20 years of experience in managing hearing loss and contributed to the development of the first FDA-approved gene therapy for genetic deafness.

His background includes positions at Decibel Therapeutics and Regeneron, where he oversaw gene therapies for genetic deafness. He has also been active at Auregen BioTherapeutics and Frequency Therapeutics. At Sensorion, he will work on SENS-601, a program targeting mutations in the GJB2 gene that cause hearing loss.

Sensorion, in collaboration with the Pasteur Institute, is developing this treatment, which has the potential to reach a large population. Frédéric Chereau, CEO of Sensorion, welcomed this appointment, which strengthens the company's clinical and medical capabilities.